PPARG and urinary bladder cancer: Additionally, pioglitazone, a peroxisome proliferator-activated receptor gamma (PPAR-γ) agonist, has been associated with an elevated bladder cancer risk, prompting caution in clinical guidelines, yet exhibits promising effects in cancers of the breast, lung, and colon [10].